E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced or Metastatic Solid Tumors or Hematologic Malignancies |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced or Metastatic Solid Tumors or Hematologic Malignancies |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029000 |
E.1.2 | Term | Neoplasm NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the safety and tolerability of atezolizumab administered by intravenous (IV) infusion every 3 weeks (q3w) to patients with locally advanced or metastatic solid tumors or hematologic malignancies
•To determine the maximum tolerated dose (MTD) and to evaluate the dose limiting toxicities (DLTs) of atezolizumab when administered as a single agent to patients by IV infusion q3w
•To identify a recommended Phase II dose of atezolizumab |
|
E.2.2 | Secondary objectives of the trial |
Pharmacokinetic Objectives:
• To evaluate the pharmacokinetics of atezolizumab when administered as a single agent
• To characterize the immunogenic potential of atezolizumab by measuring anti- atezolizumab antibodies
Activity Objective:
• To make a preliminary assessment of the anti-tumor activity of atezolizumab administered as a single agent
Exploratory Objectives:
• To make a preliminary assessment of biomarkers that might act as pharmacodynamic (PD) indicators of anti-tumor activity of atezolizumab administered as a single agent
• To make a preliminary assessment of biomarkers that might act as predictors of anti-tumor activity of atezolizumab administered as a single agent administered as a single agent |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age ≥ 18 years
• Histologically or cytologically documented, incurable or metastatic solid malignancy that is advanced (non -resectable) or recurrent and progressing since the last anti-tumor therapy and for which no recognized standard curative therapy exists. Tumor type-specific criteria are detailed in Appendix G.
• Representative tumor specimens in paraffin blocks/unstained slides with an associated pathology report
• Adequate hematologic and end organ function
• Measurable disease per RECIST
• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of atezolizumab
• ECOG: 0-1. Patients with ECOG Performance Status of 2, secondary to the underlying disease, may be enrolled after consultation with the Medical Monitor
b. Inclusion Criteria Unique to Patients Undergoing Serial Biopsy in the Serial Biopsy Dose-Expansion Cohort:
• Baseline tumor tissue samples consisting of core needle biopsies for deep tumor tissue or organs or excisional or punch biopsies for cutaneous or subcutaneous lesions will be obtained. |
|
E.4 | Principal exclusion criteria |
• Known primary central nervous system (CNS) malignancy or untreated or active CNS metastases
• History of autoimmune disease (i.e. SLE, RA, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, etc.)
• History of HIV, hepatitis B, or hepatitis C infection. Patients with past or resolved Hepatitis B are eligible. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA
• Any signs or symptoms of infection
• Malignancies other than disease under study within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., CLL Rai Stage 0, prostate cancer with Gleason score ≤ 6, and PSA ≤ 10 mg/mL, etc.)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The safety and tolerability of atezolizumab administered as a single agent therapy for patients with locally advanced or metastatic solid tumors or hematologic malignancies will be assessed using the following primary safety outcome measures:
• Incidence and nature of DLTs
• Incidence, nature, and severity of adverse events graded according to NCI CTCAE v4.0
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
As defined in the study protocol |
|
E.5.2 | Secondary end point(s) |
Safety will also be assessed using the following secondary safety endpoints:
• Incidence of anti therapeutic antibody (ATA) response and the potential correlation with PK, PD, and safety parameters
• Changes in vital signs and ECG parameters
• Changes in clinical laboratory results
• Number of cycles and dose intensity
In addition as defined in the study protocol, pharmacokinetic, activity and explanatory outcomes are defined. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
As defined in the study protocol |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability and biomarkers in tumor samples |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is defined as the completion of the last patient, last visit (LPLV) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |